Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency

Authors

Karam Khaddour, Washington University School of Medicine in St. Louis
Michael Ansstas, Washington University School of Medicine in St. Louis
George Ansstas, Washington University School of Medicine in St. Louis

Journal

Cold Spring Harbor Molecular Case Studies

Publication Date

2021

Volume

7

Issue

5

First Page

a006129

Document Type

Open Access Publication

DOI

10.1101/mcs.a006129

Rights and Permissions

Khaddour, K., Ansstas, M., & Ansstas, G. (2021). Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency. Cold Spring Harbor molecular case studies, 7(5), a006129. https://doi.org/10.1101/mcs.a006129. © 2021 Khaddour et al. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.

Recommended Citation

Khaddour, Karam; Ansstas, Michael; and Ansstas, George, "Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency." Cold Spring Harbor Molecular Case Studies. 7, 5. a006129 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10954